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ABSTRACT
Introduction: Pulmonary congestion is a common finding of heart failure (HF), but it remains unclear how
pulmonary and heart blood volumes (Vp and Vh, respectively) and extravascular lung water (EVLW) change
in stable HF and affect lung function.
Methods: Fourteen patients with HF (age 68 ± 11 y, LVEF 33 ± 8%) and 12 control subjects (age 65 ± 9
y) were recruited. A pulmonary function test, thoracic computerized tomographic (CT) scan, and contrast
perfusion scan were performed. From the thoracic scan, a histogram of CT attenuation of lung tissue was
generated and skew, kurtosis, and full-width half-max (FWHM) calculated as surrogates of EVLW. Blood
volumes were calculated from the transit time of the contrast through the great vessels of the heart.
Results: Patients with HF had greater Vp and Vh (Vp 0.55 ± 0.21 L vs 0.41 ± 0.13 L; Vh 0.53 ± 0.33 L vs
0.40 ± 0.15 L) and EVLW (skew 3.2 ± 0.5 vs 3.7 ± 0.7; kurtosis 19.4 ± 6.6 vs 25.9 ± 9.4; FWHM 73 ± 13
HU vs 59 ± 9 HU). Spirometric measures were decreased in HF (percentage of predicted: forced vital ca-
pacity 86 ± 17% vs 104 ± 9%; forced expiratory volume in 1 second 83 ± 20% vs 105 ± 11%; maximal mid-
expiratory flow 82 ± 42% vs 115 ± 43%). Vp was associated with decreased expiratory flows, and EVLW
was associated with decreased lung volumes.
Conclusions: Congestion in stable patients with HF includes expanded Vp and Vh and increased EVLW
associated with reductions in lung volumes and expiratory flows. (J Cardiac Fail 2017;23:690–696)
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Pulmonary congestion is a common clinical complica-
tion of heart failure (HF) as a result of the close functional
relationship between the heart and lungs. The failing left ven-
tricle causes altered hemodynamics that lead to accumulation
of blood centrally.1 This accumulated blood may contribute
to elevated pulmonary wedge pressure, engorgement of the
pulmonary vasculature, bronchial vasculature, and capillar-
ies, increased transudation of fluid into the interstitial space,
and increased extravascular lung water (EVLW).2,3 Because
the lung has the ability to efficiently clear fluid away from
the gas-exchanging region of the alveoli and prevent the for-
mation of edema, the degree to which EVLW persists in stable
disease remains unclear.4,5 Overall, the degree to which these
blood volumes and extravascular fluid are affected in stable
chronic disease and contribute to the congestive state is poorly
defined.
Pulmonary function deteriorates in HF with significant het-
erogeneity between individuals. Patients with HF often exhibit
changes that are both restrictive—reductions in forced vital
capacity (FVC) and total lung capacity—and obstructive—
reductions in peak expiratory flow (PEF) and maximal mid-
expiratory flow (FEF25-75).6–8 Patients with HF also exhibit
changes in lung compliance, altered ventilatory control, and
poor exertional tolerance.2,9,10 These functional limitations con-
tribute to the symptoms of dyspnea and are associated with
the development of pulmonary congestion.
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It has long been understood that the accumulation of fluid
in the lungs results in symptoms associated with HF. In pa-
tients with HF who have become acutely decompensated, fluid
accumulation in both the lung extravascular space and the lym-
phatics causes symptoms of dyspnea and exercise intolerance
that requires in-patient diuretic treatment to return fluid levels
to baseline conditions.11,12 Constriction of the bronchial vas-
culature with the use of methoxamine was shown to improve
exercise tolerance in subjects with stable chronic HF, high-
lighting the importance of bronchial circulation in this
population.13,14 In healthy subjects, rapid fluid loading has been
shown to reduce lung volumes and forced expiratory flows,
and heart transplantation in patients with severe disease, sub-
sequently reducing pulmonary pressures, improves these same
measures, suggesting that either thoracic blood volumes or
EVLW may contribute to changes in lung function.15,16 In ad-
dition, the heart and lungs must compete for space within the
thoracic cavity, where cardiomegaly and/or other changes in
vascular beds may impinge on the ability of the lungs to
expand.17
Modulation of thoracic fluid volumes affect pulmonary func-
tion in HF, but the degree to which pulmonary congestion
persists in the stable HF population and how various fluid com-
partments within the thorax impact lung function are not clear.
There are a number of compartments that have been impli-
cated as contributors, including the larger pulmonary vessels,
the capillaries, the heart, and the extravascular space. Some
of these central fluid volumes have been shown to be el-
evated in chronic heart failure, but their link to changes in
pulmonary function has not been clearly investigated.
The purpose of the present study was to (a) define how
various thoracic fluid volumes, specifically the thoracic, pul-
monary, and heart blood volumes and EVLW, are affected
in patients with stable chronic systolic HF and (b) deter-
mine the relationship between these volumes and changes in
lung function in stable chronic patients with HF. We hypoth-
esized that stable chronic patients with HF would have
increased thoracic, pulmonary, and heart blood volumes and
greater levels of EVLW than the control group resulting in
decreased pulmonary function. Further, we hypothesized that
the pulmonary blood volume would be associated with ob-
structive changes in lung function, while EVLW would be
associated with restrictive changes in lung function.
Methods
Participants
Fourteen patients with a history of HF and 12 age-matched
control subjects were recruited for this study; their charac-
teristics are reported in Table 1. Patients had ≥1 year of disease
history and were on stable medication for ≥1 month, had left
ventricular ejection fraction of <40%, a body mass index (BMI)
of <35 kg/m2, and no history of pulmonary or renal disease.
Subjects had a range of clinical severity with New York Heart
Association functional classes of I, II, and III. Control sub-
jects had no history of cardiovascular, respiratory, or metabolic
disease and BMIs <35 kg/m2. The study protocol obtained
Mayo Clinic Institutional Review Board approval, and in-
formed written consent was obtained from each subject before
participation.
Overview of Experimental Procedures
All experimental procedures were conducted within a single
day. A venipuncture blood draw was performed to obtain a
measurement of hemoglobin to rule out anemia and of cre-
atinine to verify adequate renal function. Dynamic pulmonary
function tests were performed to assess FVC, forced expi-
ratory volume in 1 second (FEV1), FEV1/FVC, FEF25-75, and
PEF according to standard methods.18 Breath-by-breath mea-
sures of minute ventilation (VE), respiratory rate (RR), tidal
volume, oxygen consumption (VO2), carbon dioxide produc-
tion (VCO2), VE/VCO2 ratio, and respiratory exchange ratio
(RER) were collected during 6 minutes of resting breath-
ing. A thoracic and electrocardiography (ECG)–gated contrast
perfusion computerized tomographic (CT) scan were ob-
tained (see details below).
Computed Tomographic Scanning
All CT scans were performed on the same scanner
(Somatom Definition Force; Siemens, Erlangen, Germany).
A thoracic CT scan was obtained for semiquantitative mea-
surement of EVLW and for alignment for the ECG-gated
contrast perfusion scan. For the perfusion scan, a region of
interest (ROI) was chosen that included the vena cava (VC),
pulmonary artery (PA), pulmonary vein (PV), and aorta (AO).
Table 1. Participant Characteristics in Control and Heart
Failure Groups
Characteristic Control Heart Failure
n (female) 12 (4) 14 (2)
Age, y 65.1 ± 2.6 67.6 ± 3.0
Height, cm 168.5 ± 2.8 175.7 ± 2.7*
Weight, kg 70.8 ± 3.9 93.9 ± 3.8*
BMI, kg/m2 24.7 ± 0.8 30.4 ± 1.1*
BSA, m2 1.8 ± 0.06 2.1 ± 0.05*
MAP, mm Hg 87.9 ± 2.0 83.6 ± 2.8
Hemoglobin, g/dL1 13.7 ± 0.3 13.7 ± 0.5
eGFR, mL/min−1/1.73 m2 77.1 ± 4.7 70.2 ± 4.8
NT-proBNP, pg/mL1 58.6 ± 13.1 1169 ± 298.9*
Left ventricular ejection fraction, % – 33.0 ± 2.0
NYHA functional class
I – 5
II – 6
III – 3
Medications
ACE inhibitor – 7
ARB – 5
Beta-blocker – 13
Digitalis – 3
Diuretic – 10
Subjects were well matched for age, but the patients with heart failure
were taller and heavier than the control subjects. No differences were ob-
served between MAP, hemoglobin, or eGFR, but patients with heart failure
had greater levels of NT-proBNP. Data are presented as ± SEM. BMI, body
mass index; BSA, body surface area, MAP, mean arterial pressure; eGFR,
estimated glomerular filtration rate; N-terminal pro–B-type natriuretic peptide;
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
*P < .05 control vs heart failure.
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Iodinated contrast (0.33 mL per kg body weight) was infused
intravenously at the antecubital fossa. Simultaneously, scan-
ning was initiated, and a scan (11 slices per scan, 4.7 mm per
slice) was taken during each diastole over a period of 30
seconds. All scans were performed while the subject was at
total lung capacity as confirmed via the Medspira Breath Hold
System (Medspira, Minneapolis, Minnesota).
Quantification of Thoracic, Pulmonary, and
Blood Volumes
Perfusion scans were used for quantification of blood
volumes. ROIs were selected in the VC, PA, PV, and AO, and
the change in the CT attenuation while the contrast passed
through each region was measured using Analyze software
(Mayo Clinic, Rochester, MN). The CT attenuation was con-
verted to contrast concentration (C) with the use of
equation 1:
C t CT t( ) = ( ) − 7 7
19 9
.
.
(1)
Where t is time.19 The gamma variate curve was fitted to
the curve for each ROI with the use of equation 2:
C t ct ea
t
b( ) = −* (2)
Where a, b, and c are arbitrary fitted constants.20 The cardiac
output (Q) was then calculated from the ROI in the PA with
the use of equation 3:
Q M
C t dt
= ( )∫ (3)
Where M is the mass of contrast agent injected.21 The mean
transit time (MTT) for each ROI was calculated with the use
of equation 4:22
MTT
t C t dt
C t dt
=
∗ ( )
( )
∫
∫ (4)
The thoracic (Vt), pulmonary (Vp), and heart (Vh) blood
volumes were calculated with the use of equations 5–7:
V Q MTT MTTt AO VC= ∗( )− (5)
V Q MTT MTTp PV PA= ∗( )− (6)
V Vt Vph = − (7)
Semiquantitative Measurement of EVLW
Thoracic CT scans were used for quantification of EVLW.
Lung tissue was segmented from surrounding tissue and large
blood vessels automatically with the use of Matlab built-in
active contour algorithms (Mathworks, Natick, Massachu-
setts). Only pixels within the range of −1000 to 0 HU were
included in the analysis. The values for the mean, skew-
ness, and kurtosis were calculated from the distribution of
CT attenuation within the segmented areas. The CT attenu-
ation of volume within the lung varies from −1000 HU
(corresponding to pure air) to 0 HU (corresponding to pure
water), with most voxels having a value between these ex-
tremes because they contain a combination of air and water.
If more of the voxels within the lung volume have an CT at-
tenuation closer to −1000 HU, the lung volume is relatively
drier, and as more water accumulates in the lung, more voxels
will move toward 0 HU. This is quantified through the mean,
skewness, kurtosis, and full-width half-max (FWHM), where
the curve is skewed to the left, has a high kurtosis, and is
narrow when the lung is dry. Conversely, as EVLW accu-
mulates, the mean shifts to the right, the skew decreases, the
kurtosis decreases, and the FWHM increases as more voxels
within the lung space are closer to 0 HU.23,24
Statistical Analysis
Statistical analysis was carried out in SPSS v20 (IBM,
Chicago, Illinois). The independent-samples Mann-Whitney
U test was used to compare subject demographics, gas ex-
change, blood volumes, EVLW measurements, and pulmonary
function between patients with HF and age-matched control
subjects. In addition, Cohen d was computed for blood volumes
and EVLW to show effect size of the respective differences.25
The interrelationships between blood volumes, EVLW, and
indexes of pulmonary function were assessed via linear re-
gression. Corrections for multiple comparisons were not made.
Demographic and gas exchange data are presented as mean
± SEM, pulmonary function measures are expressed as mean
± SEM, and blood volumes and extravascular lung water mea-
surements are expressed as median (interquartile range).
Statistical significance was accepted if P < .05.
Results
Pulmonary Gas Exchange
Measurements of resting gas exchange and breathing pattern
are reported in Table 2. VE was greater in patients with HF
compared with healthy control subjects (P < .05); all other
resting ventilatory and gas exchange indices were similar
between the groups.
Table 2. Gas Exchange and Breathing Pattern Measurements for
Control and Heart Failure Groups
Measurement Control Heart Failure
VO2, mL/min1 239 ± 15 303 ± 30
VCO2, mL/min1 188 ± 12 253 ± 25
RER 0.79 ± 0.02 0.84 ± 0.07
RR, breaths.min1 15.1 ± 0.6 16.2 ± 1.6
Tidal volume, mL 546 ± 41 699 ± 88
VE, L/min 7.9 ± 0.4 10.6 ± 1.0*
VE/VCO2 44.0 ± 1.2 44.6 ± 3.6
No differences were observed between the groups, except for patients with
HF having greater minute ventilation. Data are presented as mean ± SEM.
VO2, oxygen consumption; VCO2, carbon dioxide production; RER, respi-
ratory exchange ratio ; RR, respiratory rate; VE, minute ventilation.
*P < .05.
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Thoracic Blood Volumes
Thoracic, pulmonary, and heart blood volumes were greater
in the HF group in absolute terms (Vt 1090 ± 530 mL vs
810 ± 250 mL; Vp 550 ± 210 mL vs 410 ± 130 mL; Vh
540 ± 350 mL vs 400 ± 150 mL; P < .05). To account for dif-
ferences in body size, Vt, Vp, and Vh normalized to body
surface area (BSA) are reported in Table 3. All 3 blood
volumes were greater in the patients with HF when normal-
ized to BSA. The effect size was considered to be large for
the Vt and Vp and medium for Vh, suggesting that there is a
consistent difference in these blood volumes for the 2
populations.25
CT Quantitative Indices
The average CT attenuation distribution for both groups
is shown in Fig. 1. The mean, skew, kurtosis, and FWHM
are presented in Table 4. The HF group had distributions that
were less negative, less skewed, and wider, suggesting greater
levels of EVLW. In addition, the effect size for all 4 mea-
surements was large, suggesting that these measurements
differentiate well between groups.
Pulmonary Function
Pulmonary function measurements for both groups are
shown in Fig. 2. Absolute and percentage of predicted FVC,
FEV1, FEF25-75, and PEF were lower in patients with HF com-
pared with healthy control subject (P < .05). In contrast, FEV1/
FVC was not different between the groups.
Relationship Between Thoracic Blood Volumes and
EVLW and Pulmonary Function
Correlations between thoracic blood volumes and EVLW
and pulmonary function measurements are reported in Table 5.
In the control group, only thoracic blood volume was sig-
nificantly correlated with FEV1. In the HF group, FVC was
significantly related to the mean, skew, kurtosis, and FWHM
and FEV1 was related to the skew and kurtosis, with greater
levels of EVLW associated with decreased lung volumes.
FEV1/FVC was inversely and significantly correlated with Vt,
Vp, and Vh, and PEF was inversely correlated with Vt and Vp.
Table 3. Thoracic, Pulmonary, and Heart Blood Volumes for Control and Heart Failure Groups Normalized to Body Surface Area
Measurement Control Heart Failure P value Cohen d
Thoracic blood volume, mL/m2 430 (360–530) 640 (420–670) .015 0.91
Pulmonary blood volume, mL/m2 210 (190–260) 340 (220–360) .006 1.12
Heart blood volume, mL/m2 220 (180–270) 270 (210–360) .131 0.68
Patients with HF had a greater level of all 3 blood volumes. Data are presented as median (interquartile range).
Fig. 1. Histogram of computerized tomographic (CT) attenuation
of the lung tissue for control (solid line) and heart failure (dashed
line) subjects. For clarity, confidence intervals are not shown.
Table 4. Quantitative Computerized Tomographic Indexes for the Control and Heart Failure Groups
Index Control Heart Failure P value Cohen d
Mean, HU −860 (−869 to −822) −821 (−845 to −802) .17 0.98
Skew 3.44 (3.16–4.44) 2.99 (2.86–3.43) .27 0.94
Kurtosis 22.6 (18.6–33.4) 17.0 (15.1–23.1) .60 0.86
FWHM, HU 57.0 (50.8–69.0) 71.1 (63.1–86.1) .001 1.64
Less negative mean, lower skew and kurtosis, and higher FWHM suggest greater levels of extravascular lung water. Patients with heart failure had greater
levels of extravascular lung water as indicated by the difference in skew, kurtosis, and FWHM. Data are presented as median (interquartile range). FWHM,
full-width half-max.
Fig. 2. Spirometric measurements for control (black) and heart failure
(gray) subjects. Error bars indicate SEM. *P < .05. FVC, forced vital
capacity; FEV1, forced expiratory volume in 1 second; FEF25-75,
maximal mid-expiratory flow; PEF, eak expiratory flow.
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Greater volumes of blood were associated with decreased pul-
monary function. FEF25-75 was not associated with any
measures of thoracic blood volume or EVLW in either group.
Discussion
Pulmonary congestion is a common, complicated mani-
festation of the pathophysiology of HF. In the present study,
we sought to quantify thoracic, pulmonary, and heart blood
volumes with the use of a CT contrast perfusion method as
well as to semiquantitatively determine EVLW to under-
stand each compartment’s contribution to “pulmonary
congestion” in a stable chronic HF population and to under-
stand their respective effects on lung function. We found that
the HF population had increases in thoracic, pulmonary, and
heart blood volumes, increased EVLW, and impaired lung func-
tion compared with control subjects. Greater pulmonary blood
volume was associated with obstructive changes in the lungs
and decreases in FEV1/FVC and PEF, and increased EVLW
was related to restrictive lung changes and reductions in FVC
and FEV1. Thus, even in stable chronic HF, there are ex-
panded thoracic, pulmonary, and heart blood volumes as well
as evidence for increased EVLW consistent with subclinical
edema. Each of these changes appears to negatively affect
and contribute to the symptomology of HF.
Thoracic Blood Volumes
Traditionally, EVLW has been thought to be the main con-
tributor to pulmonary congestion.26 In our view, the expansion
of the pulmonary vascular blood volume also contributes to
the loss of pulmonary function. Thoracic blood volumes have
been quantified in a number of ways to investigate if these
compartments change with the progression of HF and other
diseases. To our knowledge, we are the first to quantify these
fluid compartments with the use of the CT contrast perfu-
sion technique described here, which is less invasive than
previously used methods based on invasive indicator dilu-
tion. Our findings are quantitatively similar to those from other
groups using invasive indicator dilution methods and quali-
tatively similar to those using positron emission tomography
(PET) methods.27,28
We found that increased thoracic, pulmonary, and heart blood
volumes were associated with reductions in FEV1/FVC ratio
and PEF. There are several possible explanations for this result.
Increases in pulmonary vascular volume may cause compres-
sion of the airways. Various studies in humans and other animals
after rapid fluid loading have shown that small vessels near small
airways become engorged and edema forms in the airway walls,
but that airways cross sectional area was maintained.29–31 One
study in dogs with the use of CT scanning found ~20% reduc-
tion in airway area with saline solution infusion.32 A previous
study in our laboratory found small reductions in the luminal
airway of the large airways after fluid loading but no differ-
ences in large airways in patients with HF.15,33 These divergent
findings confound the understanding of the relationship between
pulmonary function and thoracic blood volumes that were found
in the present study. It is possible that edema formation in the
small bronchioles changes their structural properties, making
them more susceptible to collapse, or causes changes in the
luminal walls, leading to increased airway resistance. In either
case, the equal pressure point would move distally and create
greater flow limitations.
It has been previously shown that heart volume can be a
factor associated with reduced lung volumes; however, we
did not observe that relationship in the present study.17,34 The
relationship was likely not found because only the blood
volume within the heart was measured as opposed to the entire
heart volume. Radiographically determined measures of heart
volume are more predictive than echocardiographically de-
termined measures owing to incorporation of the entire cardiac
mass versus assessment of individual chambers.35 Given that
the measure described here measured only the blood within
the heart chambers, it would be expected to have poor pre-
dictive value for the lung volumes.
Extravascular Lung Water
EVLW is traditionally thought of as the main contributor
to pulmonary congestion in HF. A histogram technique to
Table 5. Pearson Correlation Coefficients Between Spirometric Variables and Thoracic, Pulmonary, and Heart Blood Volumes and
Computerized Tomographic Quantitative Indexes for Control and Heart Failure
Variable Thoracic blood volume Pulmonary blood volume Heart blood volume Mean Skew Kurtosis FWHM
Control
FVC .27 .48 −.05 −.13 .19 .31 −.15
FEV1 .51* .47 .40 .25 −.09 .01 .17
FEV1/FVC .31 .08 .46 .35 −.22 −.22 .28
FEF25-75 .20 .09 .25 .23 −.02 −.01 .10
PEF .17 −.02 .33 .32 −.30 −.24 .32
Heart failure
FVC .39 .29 .42 −.55* .51* .49* −.53*
FEV1 −.04 −.04 −.04 −.37 .49* .47* −.38
FEV1/FVC −.64* −.50* −.67* .16 .09 .10 .11
FEF25-75 −.33 −.25 −.35 −.19 .40 .40 −.31
PEF −.46* −.51* −.38 .13 −.20 −.27 .03
Blood volumes were associated with obstructive changes in expiratory flows and EVLW with restrictive changes in lung volumes in the patients with heart
failure but not in the control subjects. Abbreviations as in Fig. 2. *P < .05.
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semiquantitatively measure differences in EVLW was
used.23,33,36 Decreased skew and kurtosis and increased FWHM,
as found here, suggest the presence of additional EVLW in
stable chronic patients with HF compared with control sub-
jects. This qualitatively matches the findings from other
laboratories that used direct measures, such as indicator di-
lution and PET techniques, and found increased EVLW in
patients with HF.37,38 This increased water likely forms because
of increased pulmonary wedge pressure. No differences were
found in the resting gas-exchange measures, suggesting the
increased EVLW is not present in the alveoli and is being di-
verted to the thick side of the alveoli-capillary membrane to
the lymphatic system.
In the present study, a relationship was found between in-
creased levels of EVLW, as measured by the CT indexes, and
restrictive changes in lung function, as indicated by de-
creased FVC and FEV1. Increased EVLW has been linked
to changes in pulmonary mechanics, specifically decreased
compliance, which would limit lung volumes, and is related
to the degree of EVLW present.39 Overall, increased EVLW
seems to be a factor in reduced lung volumes in stable
chronic HF.
Study Limitations
Four major points must be considered when interpreting
the findings of the present study. First, the patients with HF
were taller and weighed more than the control subjects. To
account for these factors, we normalized our thoracic,
pulmonary, and heart blood volumes to the subjects’ BSA
and exclusively used percentage of predicted for pulmonary
function measures. Second, the method used to measure
EVLW does not provide a quantitative measure and may be
susceptible to changes in tissue or blood volume. Although
we found increased pulmonary blood volume, most of this
would be excluded by the segmentation process before
histogram generation and calculation of the quantitative
indexes. In addition, studies have found no difference in
capillary blood volumes between HF and control subjects;
these factors suggest that this method is primarily measur-
ing differences in water content.40 Third, in some subjects,
there was incomplete washout of the dye from the aorta
during the 30-second scanning period. All subjects reached
the downward slope of the contrast washout curve, but
fitting errors could still exist as a result of extrapolation.
However, the extrapolated curves were qualitatively similar
to those fitted to a complete dataset, suggesting that the
error was small. Finally, we chose not to correct for
multiple comparisons owing to a concern that false nega-
tives could limit further investigation into these factors as
causes of reduced function in HF, the fact that a false
discovery rate was not determined before data collection,
and the relatively small sample size of the present study.
Additionally, the large effects sizes suggest that these
findings represent important consistent differences between
HF and control subjects.
Conclusion
In the present study, we sought to better define pulmo-
nary congestion in stable patients with HF by examining both
thoracic blood volumes and EVLW. The thoracic, pulmo-
nary, and heart blood volumes were quantified with the use
of a novel CT contrast–based approach. We determined that
thoracic, pulmonary, and heart blood volumes and EVLW were
increased in patients with stable chronic HF. Symptoms con-
sistent with pulmonary congestion, such as decreased lung
volumes and flows, were observed. Overall, stable chronic
patients with HF had evidence of mild increases in EVLW
that were associated with a reduction in lung volumes and
thoracic blood volumes that were were linked to reduced forced
expiratory flows. Although EVLW is a recognized sequela of
pulmonary congestion in a more acute decompensated state,
our results suggest that vascular volumes are expanded in
the thorax, that EVLW is elevated, and that both contribute
to the altered lung function and symptoms of moderate
chronic HF.
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